Sabatolimab (MBG453) – New Clinical Study for MDS Patients

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

Sabatolimab (MBG453)

  1. SUB-TYPE OF MDS: MDS patients and Chronic Myelomonocytic leukaemia -2 patients who require first-line treatment
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: Sabatolimab (MBG453)
  4. Aims and benefits: MBG453 is an antibody that binds to a specific receptor on T-cells. In so doing, it abolishes the inhibitory effect that tumour cells have on T-cells and enhances the ability of the T-cells to destroy tumour cells. This Phase 3 trial seeks to determine the effectiveness of using MBG453 in combination with Azacitidine. It is a double-blind placebo controlled study. The main aim is to compare the overall survival with MBG453 plus Azacitidine versus placebo plus Azacitidine.
  5. Primary outcome: To determine overall survival.
  6. Secondary outcome: Assessment of the effects on quality of life, red cell transfusion-free intervals and time to disease progression.

  1. Basic inclusion criteria:
    • Intermediate, High or Very High Risk Myelodysplastic Syndrome based on the IPSS-R OR Morphologically confirmed Chronic Myelomonocytic leukaemia -2
    • Azacitidine is indicated
    • Not eligible for intensive chemotherapy
    • Not eligible for haemopoietic stem cell transplant
    • ECOG of ≤ 2
  2. Basic exclusion criteria:
    • Prior therapy with immune checkpoint inhibitors
    • Previous first line treatment for Intermediate, High or Very High Risk Myelodysplastic Syndrome OR Chronic Myelomonocytic leukaemia -2
    • Diagnosis of acute myeloid leukaemia
    • Diagnosis of therapy related myeloid neoplasm
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Novartis Investigative Site Edinburgh, United Kingdom, EH4 2XU
    • Novartis Investigative Site Nottingham, United Kingdom, NG5 1PB

If you think this information is relevant to you, please discuss it with your own physician

Free donations by shopping

Sign-up to Download our Free Patient Handbook!

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MDS UK Patient Support Group will use the information you provide on this form to be in touch with you and to provide updates.